Clinical Trial Goal
To find out:
- The highest dose of ONM-501 that's safe to give with cemiplimab
- If the combination of ONM-501 and cemiplimab is safe and works well to treat lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have lymphoma that has relapsed or is refractory
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Cemiplimab is a monoclonal antibody that targets PD-1/PD-L1 in certain cells.
ONM-501 is a dual-activating polyvalent STING agonist that doctors believe will find and attack cancer cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
ONM-501 is a dual-activating polyvalent STING agonist that doctors believe will find and attack cancer cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Cemiplimab – Given as intravenous (IV) infusion. The dose you'll get depends on when you start the trial and how safe it has been
- ONM-501 – Given as an injection. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved ONM-501.
Locations
Sponsors
lead: OncoNano Medicine, Inc.
